Sensorion Secures $15 Million in Funding to Advance Novel Hearing Loss Therapies

Sensorion, a cutting-edge clinical-stage biotechnology company specializing in developing innovative therapies for hearing loss disorders, has recently raised an impressive $15,000,000 in funding. This significant financial boost will further support Sensorion's pioneering work within the field of hearing loss. Their current clinical-stage portfolio includes SENS-401 (Arazasetron), an advanced Phase 2 product tackling Cisplatin-Induced Ototoxicity. Additionally, in collaboration with Cochlear Limited, Sensorion is also progressing with studies on SENS-401 for patients undergoing cochlear implantation. Moreover, Sensorion's strategic partnership with the prestigious Institut Pasteur is dedicated to genetic research in hearing impairments, leading to the development of gene therapy programs like OTOF-GT and GJB2-GT aimed at addressing hereditary forms of deafness. This latest funding injection will undoubtedly propel Sensorion's groundbreaking research efforts to bring transformative solutions to those affected by hearing loss, emphasizing their commitment to advancing the field of auditory healthcare.